These blog posts explore GP2’s work in further understanding the genetic architecture of Parkinson’s disease.
Adding a layer of compute to connect two massive datasets is where we are headed. Mike Nalls, Hampton Leonard, Matt Bookman, and Eline Appelmans outline the partnership between The Global Parkinson’s Genetics Program (GP2) and Accelerating Medicines Partnership: Parkinson's Disease (AMP PD) to be your one-stop shop for PD genetic and genomic data in this new blog post.
Christine Klein leads the GP2 Monogenic Hub. In this post Christine shares how her interest in Parkinson’s disease genetics was sparked, which genes have been discovered so far, and the questions which are still to be answered.
In GP2, underlying data, analytical processes, and results will be made available to the research community as quickly as possible, with minimal barriers to access and use. The latest blog post by Bradford Casey highlights the value and importance of open science.